Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Scilex's gross profit for the twelve months ending Jun 30, 2026 was $50.91M, down 34.8% year over year. For fiscal 2025 it was $125.80M, down 24.9% from the year before. The highest annual figure on record is $167.40M in fiscal 2024.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.80M | -24.9% |
| FY2024 | Dec 31, 2024 | $167.40M | +438.9% |
| FY2023 | Dec 31, 2023 | $31.06M | +14.0% |
| FY2022 | Dec 31, 2022 | $27.24M | -1.6% |
| FY2021 | Dec 31, 2021 | $27.68M | +29.3% |
| FY2020 | Dec 31, 2020 | $21.41M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $15.80M | -60.0% |
| Q1 FY2026 | Mar 31, 2026 | $25.70M | +45.2% |
| Q4 FY2025 | Dec 31, 2025 | $2.18M | -78.7% |
| Q3 FY2025 | Sep 30, 2025 | $7.23M | -32.2% |
| Q2 FY2025 | Jun 30, 2025 | $39.50M | +229.7% |
| Q1 FY2025 | Mar 31, 2025 | $17.70M | +151.3% |
| Q4 FY2024 | Dec 31, 2024 | $10.21M | +14.2% |
| Q3 FY2024 | Sep 30, 2024 | $10.67M | +58.6% |
| Q2 FY2024 | Jun 30, 2024 | $11.98M | +42.5% |
| Q1 FY2024 | Mar 31, 2024 | $7.04M | +0.8% |
| Q4 FY2023 | Dec 31, 2023 | $8.94M | +20.7% |
| Q3 FY2023 | Sep 30, 2023 | $6.73M | -13.4% |
| Q2 FY2023 | Jun 30, 2023 | $8.41M | +31.4% |
| Q1 FY2023 | Mar 31, 2023 | $6.99M | +23.3% |
| Q4 FY2022 | Dec 31, 2022 | $7.41M | – |
| Q3 FY2022 | Sep 30, 2022 | $7.77M | – |
| Q2 FY2022 | Jun 30, 2022 | $6.40M | – |
| Q1 FY2022 | Mar 31, 2022 | $5.67M | – |